A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

  • STATUS
    Recruiting
  • End date
    Aug 31, 2025
  • participants needed
    17
  • sponsor
    CellSeed Inc.
Updated on 13 August 2021

Summary

The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial esophageal cancer in the steroid administration risk group.

Details
Condition Superficial Esophageal Cancer
Treatment CLS2702C/CLS2702D
Clinical Study IdentifierNCT04689594
SponsorCellSeed Inc.
Last Modified on13 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients who plan to undergo ESD for the treatment of superficial esophageal cancer
Patients aged >=20 years at the time of consent
Patients with no clinical metastasis (cN0M0) by cervical to abdominal CT
Patients with an endoscopically diagnosed depth of wall invasion remaining in the epithelium (EP) or lamina propria mucosae (LPM)
Patients with a tumor diagnosed as >=50% and <100% of circumference, and with prediction that resection circumference will be >=75% and <100%
Patients with a tumor the major axis is <=50 mm, and with prediction that a major axis of a resection will be <=80 mm
If the patient has multiple lesions, the circumference of all minor lesions other than the one lesion with the largest circumference (major lesion) must be <50%. However, if it is predicted that the major axis of the mucosal defect is >80 mm due to treating the major and minor lesions and assembling ulcers after the treating, the patient is excluded
Patients with squamous cell carcinoma (including high-grade intraepithelial neoplasia) as confirmed by biopsy
Patients whose lesion is confirmed to be localized in the thoracic esophagus (lesions in the cervical esophagus or abdominal esophagus will be excluded). The location of the lesion will be determined by endoscopy
Patients who have not received pretreatment for esophageal cancer. Treatment by ESD for superficial esophageal cancer for which the depth of wall invasion has been assessed to remain in the epithelium (EP) or lamina propria mucosae (LPM) is not included in the definition of pretreatment. However, patients who have a scar due to previous ESD in the major or minor lesions will be excluded from the study
Patients with an ECOG Performance Status (PS) of 0 or 1
Patients in whom a commonly used endoscope with a tip diameter of 8.9 mm can pass
Patients with a dysphagia score of 0
Patients whose laboratory values within 28 days before enrolment meet all of the following criteria
White blood cell count: >=4,000/microL
Platelet count: >=100,000/microL
AST: <=100 IU/L
ALT: <=100 IU/L
Total bilirubin: <=2.0 mg/dL
Serum creatinine: <=2.0 mg/dL
Patients who have received sufficient explanation about the study and provided written voluntary consent
Patients who meet any of the following criteria
With fibrous nodule shadow on IGRA negative diagnostic imaging
Required continuous systemic administration of immunosuppressants
With diabetes with blood glucose level of 180 mg/dL or more 2 hours after meal even with insulin
With 7.0% or more of hemoglobin A1c (HbA1c, (International standard value (NGSP value)) even if taking 2 or more drug treatments for more than 3 months
With high blood pressure which does not reach the target value even if taking 2-3 antihypertensive drugs or reach it with 4 or more antihypertensive drugs
With glaucoma, posterior capsule cataract or herpes simplex keratitis (Ophthalmology consultation is not mandatory)
With a risk of administration of corticosteroids based on medical judgment

Exclusion Criteria

Patients with cardiac disease (myocardial infarction, unstable angina, and heart failure), renal disease (nephrotic syndrome and kidney failure)
Patients who have an active (within 1 year) malignancy other than esophageal cancer
Patients with active bacterial, fungal, or viral infection
Patients who are being treated with a corticosteroid except for topical corticosteroids (ointments and creams) and oral ointments or patches used for treating stomatitis after oral mucosal tissue taken from D-16 to D-1
Patients who are positive for any of serological test (HBs antigen, HBc antibody/HBs antibody, HCV antibody, HIV-1/2 antibody, HTLV-1 antibody, syphilis treponema antibody) or nucleic acid amplification test (HBV-DNA, HCV-RNA, HIV-RNA). However, this does not apply if the HBs antibody is positive and HBV-DNA is negative and the reason is clear that he was vaccinated with the hepatitis B vaccine
Patients with a mental disorder that is difficult to control
Pregnant women, lactating women, and potentially pregnant women
Patients who have participated in another clinical study within 6 months, those who are participating in another clinical study, and those who plan to participate in another clinical study during participation in this study
Patients from whom tissues cannot be collected due to a disease (e.g., stomatitis, erosion, mass, and blister) in the oral mucosa at the tissue collection site
Patients with a history of hypersensitivity to antibiotic preparations (ampicillin sodium, sulbactam sodium, streptomycin sulfate, gentamicin sulfate, or amphotericin B) or who have taken drugs that may affect the study (within 28 days before enrolment)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note